Fig. 1 · Structure

Documents & Downloads

Sesamin (Fagarol)

Cat. No. A10837 CAS 607-80-7
Sesamin is a lignan isolated from the bark of Fagara plants and from sesame oil.

In Stock

Publications for Sesamin

1 publication citing this product

  1. Hiroaki Watanabe, .et al. , Biol Pharm Bull, 2020, 43(4):688-692 PMID: 32238710

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Sesamin inhibited recombinant human CYP4F2 and showed time- and NADPH-dependent inactivation in a luciferin-substrate assay. These enzyme experiments support metabolism-dependent inhibition; the responsible intermediate remains unidentified. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
Daoy ED50 > 20 μg/mL Cytotoxicity against human DaOY cells after 3 days by MTT assay [PMID: 21115251]
HeLa ED50 > 20 μg/mL Cytotoxicity against human HeLa cells after 3 days by MTT assay [PMID: 21115251]
HEp-2 ED50 > 20 μg/mL Cytotoxicity against human Hep2 cells after 3 days by MTT assay [PMID: 21115251]
HepG2 EC50 > 60 μM Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay [PMID: 22381047]
HepG2 IC50 229 μM Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay [PMID: 31784199]
HepG2 IC50 9.4 μM Inhibition of TNFalpha-induced NFkappaB transcriptional activity in human HepG2 cells pretreated for 1 hr before TNFalpha challenge by luciferase reporter gene analysis [PMID: 22381047]
MCF7 ED50 > 20 μg/mL Cytotoxicity against human MCF7 cells after 3 days by MTT assay [PMID: 21115251]
SH-SY5Y IC50 229 μM Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay [PMID: 31784199]

In Vitro Studies

In DLD-1 colon cancer reporter cells, sesamin did not significantly suppress basal COX-2 promoter activity at concentrations up to 100 µM after 48 h. This negative result limits generalization of anti-inflammatory activity across cellular assays. [2]

Direct inhibition of recombinant human CYP4F2

Biochemical assay · Commercial recombinant human CYP4F2 microsomes with reductase and cytochrome b5; luciferin-4F2/3 O-dealkylation assay [1]

Sesamin inhibited the reporter-substrate reaction. Kinetics supported mixed-type inhibition; the reported apparent Ki was fitted using a Michaelis–Menten mixed model although substrate kinetics followed a Hill model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Luciferin-4F2/3 O-dealkylase activityIC50 0.381 ± 0.031 µM[1]
Mixed-type inhibition of luciferin-4F2/3 O-dealkylationApparent Ki 0.272 ± 0.041 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–2.5 µM sesamin with 5 µM luciferin-4F2/3; kinetic series: 0–0.5 µM sesamin and 1–10 µM substrate
Exposure duration
20 min at 37°C
Method
Luminescence assay with an NADPH-generating system; zero-sesamin control
Vehicle
0.5% DMSO in all samples
Reported limits
No catalog number, lot, analytical stereochemistry or purity reported.
Methods and source locations

Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin

Reporter-substrate biochemical inhibition only; no direct binding, cellular efficacy or clinical blood-pressure claim.

Materials; Inhibition Studies; Statistical Analysis; Results: Inhibition of Human CYP4F2; Figs 1–2 and captions; Table 1

Luciferin-4F2/3 O-dealkylase activity: Nonlinear logistic concentration-response fit; mean ± SD; 3 independent experiments per Fig. 1 caption — Results: Inhibition of Human CYP4F2; Fig. 1/caption; Inhibition Studies

Mixed-type inhibition of luciferin-4F2/3 O-dealkylation: Mixed-type Michaelis–Menten model used as an approximation to Hill kinetics; mean ± SD — Results: Inhibition of Human CYP4F2; Fig. 2; Table 1; Inhibition Studies

Time- and NADPH-dependent CYP4F2 inactivation

Biochemical assay · Same recombinant human CYP4F2 preparation and reporter-substrate system as the direct-inhibition study [1]

Preincubation enhanced inhibition. Time/concentration kinetics and matched NADPH controls supported metabolism-dependent inactivation. The responsible metabolic intermediate was not identified.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Luciferin-4F2/3 O-dealkylase inhibition with versus without preincubationIC50 20 min: 0.0634 ± 0.0106 µM; 0 min: 0.399 ± 0.013 µM[1]
Time-dependent loss of CYP4F2 activitykinact 0.354 ± 0.020 min−1[1]
Concentration dependence of CYP4F2 inactivationKI 1.12 ± 0.05 µM[1]
Residual enzyme activity after preincubationNADPH requirement Sesamin or NADPH alone did not change activity; both together decreased activity (P < 0.001 for the bracketed comparison in Fig. 5).[1]

Literature-Reported Treatment Conditions

Treatment concentration
IC50 shift: 0–2.5 µM sesamin; inactivation kinetics: 0–1 µM; NADPH-dependence comparison: 0.2 µM sesamin
Exposure duration
IC50 shift: 0 or 20 min preincubation; kinetic preincubation: 0, 2, 4 or 6 min at 37°C; NADPH control: 6 min
Method
Preincubation then reporter activity assay; kinetic aliquots diluted tenfold into assay mixture
Vehicle
DMSO; assay method specifies final 0.5% in all samples
Co-treatment
NADPH-generating system compared with its omission; no second therapeutic compound
Reported limits
No current-lot characterization; chemical identity of the inactivating metabolite remains unknown.
Methods and source locations

Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin

Enzyme inactivation supported by functional controls; molecular intermediate and clinical relevance remain unresolved.

Inactivation Studies; Statistical Analysis; Results: Metabolism-Dependent Inhibition; Figs 3–5/captions; Discussion

Luciferin-4F2/3 O-dealkylase inhibition with versus without preincubation: Corresponding control activities; mean ± SD; 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 3/caption; Inactivation Studies

Time-dependent loss of CYP4F2 activity: Nonlinear fit of observed inactivation rate; mean ± SD; 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 4/caption; Inactivation Studies

Concentration dependence of CYP4F2 inactivation: Half-maximal inactivation concentration; mean ± SD; 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 4/caption; Inactivation Studies

Residual enzyme activity after preincubation: 6-min preincubation; sesamin 0.2 µM; Bonferroni comparison; mean ± SD, 3 independent experiments — Results: Metabolism-Dependent Inhibition; Fig. 5/caption; Inactivation Studies

Limited effect on basal COX-2 promoter activity in DLD-1 cells

Cell-based study · Human DLD-1/COX-2-B2-βGal-BSD reporter cells [2]

Sesamin did not significantly suppress basal COX-2 promoter activity up to 100 µM. Reporter activity was normalized to viable cell number; the authors reported no remarkable suppression of cell proliferation by the tested compounds in the MTT assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal COX-2 promoter reporter activitySignificance versus untreated control No significant suppression up to 100 µM sesamin.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 12.5, 25, 50 and 100 µM sesamin
Exposure duration
48 h
Method
β-Galactosidase reporter assay with ONPG; normalization by MTT viability assay
Co-treatment
Sesamol and other sesame constituents were tested separately, not co-treatments.
Reported limits
Treatment solvent is not specified in the retrieved reporter methods. Methods and Fig. 2 caption disagree on seeding density (2 × 10^4 versus 2 × 10^5 cells/well); no density is adopted.
Methods and source locations

Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin

Basal promoter reporter result in one human cancer cell line; no conclusion about stimulated inflammation or sesamin animal antitumor efficacy.

Chemicals; Cell culture; Measurements of cell viability; Reporter gene assay; Statistical analysis; first Results subsection; Fig. 2B/caption

Basal COX-2 promoter reporter activity: β-Galactosidase normalized for MTT viable-cell number at 48 h; triplicate wells, SD; Fig. 2 representative of >3 independent experiments; Bonferroni z test as reported — Abstract; first Results subsection; Fig. 2B/caption; Reporter gene assay and Statistical analysis

In Vivo Studies

In a 10-day rat feeding study, 0.2% dietary sesamin alone did not significantly lower total cholesterol relative to the high-cholesterol control. At day 10, combining sesamin with 1.0% dietary α-tocopherol lowered total and LDL cholesterol relative to the high-cholesterol control and individual-supplement groups. [3]

Sesamin alone and with α-tocopherol in cholesterol-fed rats

Animal study · Male Sprague-Dawley rats purchased at 5 weeks, acclimated for 6 days; five groups of n = 6 [3]

At day 10, sesamin alone did not significantly lower total cholesterol relative to the high-cholesterol control. Co-feeding sesamin and α-tocopherol lowered total and LDL cholesterol relative to the high-cholesterol control and individual-supplement groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma total cholesterol during feedingGroup comparison At day 10, no significant difference among high-cholesterol control, α-tocopherol alone and sesamin alone; combined treatment was lower than these groups.[3]
Plasma LDL cholesterol during feedingGroup comparison At day 10, combined treatment lowered LDL cholesterol relative to high-cholesterol control and both individual-supplement groups.[3]

Conditions shared by the study groups

Route
Oral, incorporated in diet
Frequency
Ad libitum
Treatment course
10 days
Vehicle
Diet; compositions in Table 1
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Control diet
No added sesamin or α-tocopherol
Cholesterol-free reference dietReference group for dietary hypercholesterolemia.[3]
High-cholesterol control
1.0% cholesterol diet; no sesamin or α-tocopherol
Control dietCholesterol increased under the high-cholesterol diet.[3]
Sesamin alone
0.2% sesamin added to high-cholesterol diet
High-cholesterol diet aloneNo significant reduction in total cholesterol relative to high-cholesterol control.[3]
α-Tocopherol alone
1.0% α-tocopherol added to high-cholesterol diet; supplied as DL-α-tocopherol acetate
High-cholesterol diet aloneNo significant reduction in total cholesterol relative to high-cholesterol control.[3]
Sesamin plus α-tocopherol
0.2% sesamin + 1.0% α-tocopherol added to high-cholesterol diet
High-cholesterol control and both single-supplement groupsAt day 10, lower total and LDL cholesterol than high-cholesterol control and single-supplement groups.[3]
Control diet
Model: Male Sprague-Dawley rats; n = 6 per group
Reported limits: No individual mg/kg body-weight exposure reported.
High-cholesterol control
Model: Male Sprague-Dawley rats; n = 6 per group
Reported limits: No individual mg/kg body-weight exposure reported.
Sesamin alone
Model: Male Sprague-Dawley rats; n = 6 per group
Reported limits: No individual mg/kg body-weight exposure reported.
α-Tocopherol alone
Model: Male Sprague-Dawley rats; n = 6 per group
Reported limits: No individual mg/kg body-weight exposure reported.
Sesamin plus α-tocopherol
Model: Male Sprague-Dawley rats; n = 6 per group
Reported limits: No individual mg/kg body-weight exposure reported.
Methods and source locations

Compound reported in the paper: Sesamin; Compound label in the paper: Sesamin

Short-term rat feeding context only; the combination outcome cannot be assigned to sesamin alone.

Materials; Animals and diets; Biochemical profiles in plasma and liver; Statistical analyses; Results: Biochemical profiles in plasma; Fig. 2/caption (p. 411)

Plasma total cholesterol during feeding: Enzymatic biochemical analyzer; mean ± SEM, n = 6; one-way ANOVA and Tukey comparisons — Results: Biochemical profiles in plasma; Fig. 2A/caption, p. 411

Plasma LDL cholesterol during feeding: Enzymatic biochemical analyzer; mean ± SEM, n = 6; Tukey comparison, P < 0.05 for groups without a common letter — Results: Biochemical profiles in plasma; Fig. 2B/caption, p. 411

Control diet · Animals and diets; Table 1; Results: Biochemical profiles in plasma; Fig. 2/caption

High-cholesterol control · Animals and diets; Table 1; Results: Biochemical profiles in plasma; Fig. 2/caption

Sesamin alone · Animals and diets; Table 1; Results: Biochemical profiles in plasma; Fig. 2/caption

α-Tocopherol alone · Animals and diets; Table 1; Results: Biochemical profiles in plasma; Fig. 2/caption

Sesamin plus α-tocopherol · Animals and diets; Table 1; Results: Biochemical profiles in plasma; Fig. 2/caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 607-80-7
Formula C20H18O6
Molecular Weight 354.4
Synonyms Fagarol; Sezamin
SMILES
C1[C@H]2[C@H](CO[C@@H]2C3=CC4=C(C=C3)OCO4)[C@H](O1)C5=CC6=C(C=C5)OCO6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 62 mg/mL (174.96 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Hiroaki Watanabe, Satoshi Yamaori, Shinobu Kamijo, et al. In Vitro Inhibitory Effects of Sesamin on CYP4F2 Activity Biological and Pharmaceutical Bulletin (2020). PMID: 32238710 DOI: 10.1248/bpb.b19-00953 Source material
  2. [2] Satomi Shimizu, Gen Fujii, Mami Takahashi, et al. Sesamol suppresses cyclooxygenase-2 transcriptional activity in colon cancer cells and modifies intestinal polyp development in ApcMin/+ mice Journal of Clinical Biochemistry and Nutrition (2014). PMID: 24688218 DOI: 10.3164/jcbn.13-91 Source material
  3. [3] Tomohiro Rogi, Namino Tomimori, Yoshiko Ono, et al. The Mechanism Underlying the Synergetic Hypocholesterolemic Effect of Sesamin and α-Tocopherol in Rats Fed a High-Cholesterol Diet Journal of Pharmacological Sciences (2011). PMID: 21372506 DOI: 10.1254/jphs.10287FP Source material

Publications

1 publication citing this product

  1. Hiroaki Watanabe, .et al. , Biol Pharm Bull, 2020, 43(4):688-692 PMID: 32238710

Added to your cart

View Cart Checkout
Loading...